Publicação científica trimestral do CREMERJ - volume 2 - número 3 - 2023

59 Med. Ciên. e Arte , Rio de Janeiro, v.2, n.3, p.38-60, jul-set 2023 Vacinação no idoso Ronaldo Rozenbaum 35. https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html 36. https://www.cdc.gov/mmwr/volumes/72/rr/rr7203a1.htm#T2_down 37. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341. 38. Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1. 39. United States Centers for Disease Control and Prevention. Shingles Surveillance. DOI: http://www.cdc. gov/shingles/surveillance.html (Acesso em: 01 Jul 2016). 40. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32:1481. 41. Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008; 115:S3. 42. Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157:1217. 43. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342:341. 44. UpToDate: herpes zoster Mary A Albrecht, MD; Myron J Levin, MD. This topic last updated: Feb 24, 2022. 45. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087. 46. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016; 375:1019. 47. Boutry C, Hastie A, Diez-Domingo J, et al. The Adjuvanted Recombinant Zoster Vaccine Confers Long- Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. Clin Infect Dis 2022; 74:1459. 48. Schwarz TF, Volpe S, Catteau G, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 2018; 14:1370. 49. Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR. Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study. Clin. Infect. Dis. 2021; 73, 949-956. 50. Izurieta HS, Wu X, Forshee R, Lu Y, Sung H-M, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, et al. Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure. Clin. Infect. Dis. 2021; 73, 941-948. 51. Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:80. 52. https://www.uptodate.com/contents/vaccination-for-the-prevention-of-shingles-herpes-zoster. 53. Colindres R, Wascotte V, Brecx A, et al. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother 2020; 16:2628. 54. Hesse EM, Shimabukuro TT, Su JR, et al. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018. MMWR Morb Mortal Wkly Rep 2019; 68:91. 55. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018; 67:103. 56. https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/recommendations.html 57. https://sbim.org.br/images/calendarios/calend-sbim-idoso.pdf 58. https://sbim.org.br/covid-19